Literature DB >> 11401069

Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis.

C von Bredow1, P Birrer, M Griese.   

Abstract

Inflammation and proteolytic processes play an important role in the progression of cystic fibrosis (CF) lung disease. The goal of this study was to describe bronchoalveolar lavage fluid (BALF) protein pattern of CF patients in comparison to controls and to assess if there is proteolytic degradation of surfactant protein A (SP-A), an important innate host defence component of the lungs. BALFs from 17 clinically stable CF patients and from eight healthy children were separated by two-dimensional gel electrophoresis. Silver staining was used to show BALF proteins and Western blotting to detect SP-A isoforms. In CF, BALF proteins of a low molecular weight < or = 20 kD were more abundant than in controls. Various proteins were seen in CF which were not present in controls and vice versa. Degradation of SP-A was present in 15 of 17 CF BALFs but in none of the controls, in contrast polymeric isoforms were seen in all controls and in four of 17 CF patients. Proteolytic damage to surfactant protein A and significant changes of normal bronchoalveolar lavage fluid proteins occur in lungs of cystic fibrosis patients. Identification of altered bronchoalveolar lavage fluid proteins may give new insights into pathogenic mechanisms and provide new targets for therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401069     DOI: 10.1183/09031936.01.17407160

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

1.  Exploration of the normal human bronchoalveolar lavage fluid proteome.

Authors:  Jinzhi Chen; Soyoung Ryu; Sina A Gharib; David R Goodlett; Lynn M Schnapp
Journal:  Proteomics Clin Appl       Date:  2008-04       Impact factor: 3.494

2.  Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics.

Authors:  Fiammetta Piersigilli; TuKiet T Lam; Pamela Vernocchi; Andrea Quagliariello; Lorenza Putignani; Zubair H Aghai; Vineet Bhandari
Journal:  Metabolomics       Date:  2019-02-02       Impact factor: 4.290

Review 3.  Shotgun MS proteomic analysis of bronchoalveolar lavage fluid in normal subjects.

Authors:  Elizabeth V Nguyen; Sina A Gharib; Lynn M Schnapp; David R Goodlett
Journal:  Proteomics Clin Appl       Date:  2014-10       Impact factor: 3.494

Review 4.  Human body fluid proteome analysis.

Authors:  Shen Hu; Joseph A Loo; David T Wong
Journal:  Proteomics       Date:  2006-12       Impact factor: 3.984

5.  Staphylococcus aureus elicits marked alterations in the airway proteome during early pneumonia.

Authors:  Christy L Ventura; Roger Higdon; Laura Hohmann; Daniel Martin; Eugene Kolker; H Denny Liggitt; Shawn J Skerrett; Craig E Rubens
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

6.  Surfactant protein A modulates the inflammatory response in macrophages during tuberculosis.

Authors:  Jeffrey A Gold; Yoshihiko Hoshino; Naohiko Tanaka; William N Rom; Bindu Raju; Rany Condos; Michael D Weiden
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

7.  Effect of cysteine 85 on biochemical properties and biological function of human surfactant protein A variants.

Authors:  Guirong Wang; Catherine Myers; Anatoly Mikerov; Joanna Floros
Journal:  Biochemistry       Date:  2007-06-20       Impact factor: 3.162

Review 8.  The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.

Authors:  H Clark; K Reid
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

9.  Proteolysis of surfactant protein D by cystic fibrosis relevant proteases.

Authors:  C von Bredow; A Wiesener; M Griese
Journal:  Lung       Date:  2003       Impact factor: 2.584

10.  Linkage of neutrophil serine proteases and decreased surfactant protein-A (SP-A) levels in inflammatory lung disease.

Authors:  F Rubio; J Cooley; F J Accurso; E Remold-O'Donnell
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.